MedTech Acquisition Corporation - Class A
News
Critical Survey: MedTech Acquisition (NASDAQ:MTAC) and CareDx (NASDAQ:CDNA)
Zolmax CareDx (NASDAQ:CDNA Get Free Report) and MedTech Acquisition (NASDAQ:MTAC Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, ...\n more…
MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders
Business Wire MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech or the Company) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the Special Meeting). The Special Meeting is being held to vote on certain proposals related to the...\n more…
MedTech Acquisition (NASDAQ:MTAC) versus Castle Biosciences (NASDAQ:CSTL) Head-To-Head Analysis
Ticker Report MedTech Acquisition (NASDAQ:MTAC Get Free Report) and Castle Biosciences (NASDAQ:CSTL Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, ...\n more…
MedTech Acquisition (NASDAQ:MTAC) vs. Exagen (NASDAQ:XGN) Head-To-Head Survey
Zolmax MedTech Acquisition (NASDAQ:MTAC Get Rating) and Exagen (NASDAQ:XGN Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst ...\n more…
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting
Business Wire TriSalus Life Sciences Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data...\n more…
Head-To-Head Comparison: MedTech Acquisition (NASDAQ:MTAC) versus Aclarion (NASDAQ:ACON)
Zolmax MedTech Acquisition (NASDAQ:MTAC Get Rating) and Aclarion (NASDAQ:ACON Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ...\n more…